Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.69 |
| ▸ | RXRB | P28702 | 2/20 | 0.69 |
| ▸ | RXRG | P48443 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 2/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.48 |
| ▸ | FNTB | P49356 | 1/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24726523 | 0.89 | RXRA (0.58) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL6713317 | 0.86 | EGFR (0.55) | RXRARXRBRXRGEGFRCA12 | |
| SCHEMBL28189889 | 0.85 | EGFR (0.68) | EGFRCA12CA1CA2CA9 | |
| SCHEMBL2627834 | 0.83 | CA1 (0.56) | EGFRCA12CA1CA2CA9 | |
| SCHEMBL27589486 | 0.83 | TSHR (0.64) | EGFRCA12CA1CA2CA9 | |
| SCHEMBL4601619 | 0.82 | RXRA (1.00) | RXRARXRBRXRGEGFRPTPN5 | |
| SCHEMBL26816758 | 0.82 | RXRA (0.76) | RXRARXRBRXRGCA1CA2 | |
| SCHEMBL84441 | 0.82 | TSHR (0.53) | NPC1MAPTRAB9ATSHRHDAC4 | |
| SCHEMBL68931 | 0.82 | CA12 (0.69) | EGFRCA12CA1CA2CA9 | |
| SCHEMBL5943729 | 0.81 | RXRA (0.69) | RXRARXRBRXRGPTPN5HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9751897-B1 | Derivatives of Bodipy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751897-B1 | Derivatives of Bodipy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170233414-A1 | DERIVATIVES OF BODIPY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233414-A1 | DERIVATIVES OF BODIPY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | RXRA 2947/4885RXRB 2011/4885RXRG 2024/4885 |
| US-20170233414-A1 | DERIVATIVES OF BODIPY | NPC1L1, NPC1, ABCB4 | RXRA 1498/4885RXRB 383/4885RXRG 1134/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | RXRA 303/4885RXRB 156/4885RXRG 136/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | RXRA 753/4885RXRB 785/4885RXRG 985/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | RXRA 1285/4885RXRB 1380/4885RXRG 1658/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | RXRA 807/4885RXRB 348/4885RXRG 368/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | RXRA 303/4885RXRB 156/4885RXRG 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.